Notably, in the IMMUNOTARGET study that evaluated the efficacy of PD-1/L1 inhibitors alone in patients with NSCLC with driver gene mutations, none of the twenty-three patients with ALK fusions had a disease response (29). Here, ALK is linked to non-small cell lung carcinoma.